Stem definition | Drug id | CAS RN |
---|---|---|
antiviral, monoclonal antibodies | 5436 | 2135632-29-8 |
Molecule | Description |
---|---|
Synonyms:
|
Atoltivimab in combination with odesivimab and maftivimab has been approved as INMAZEB for the treatment of infection caused by Zaire ebolavirus. INMAZEB is a combination of the three recombinant human IgG1kappa monoclonal antibodies that inhibit Zaire ebolavirus, each targeting the Zaire ebolavirus glycoprotein (GP). Maftivimab is a neutralizing antibody that blocks entry of the virus into susceptible cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcyRIIIa signaling when bound to its target. Odesivimab also binds to the soluble form of Zaire ebolavirus glycoprotein (sGP). Atoltivimab combines both neutralization and FcgammaRIIIa signaling activities.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 14, 2020 | FDA | REGENERON PHARMACEUTICALS |
None
None
None
None
Source | Code | Description |
---|---|---|
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ebola virus disease | indication | 37109004 | DOID:4325 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Low affinity immunoglobulin gamma Fc region receptor III-A | Membrane receptor | ANTIBODY BINDING | EC50 | 8.64 | DRUG LABEL | DRUG LABEL | |||
Envelope glycoprotein | Glycoprotein | ANTIBODY BINDING | Kd | 8.11 | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
D11468 | KEGG_DRUG |
CHEMBL4298183 | ChEMBL_ID |
C000711948 | MESH_SUPPLEMENTAL_RECORD_UI |
C000711952 | MESH_SUPPLEMENTAL_RECORD_UI |
DB15898 | DRUGBANK_ID |
1052216001 | SNOMEDCT_US |
C5417452 | UMLSCUI |
11032 | INN_ID |
2461338 | RXNORM |
FJZ07Q63VY | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-018 | INJECTION, SOLUTION | 241.70 mg | INTRAVENOUS | BLA | 29 sections |
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-018 | INJECTION, SOLUTION | 241.70 mg | INTRAVENOUS | BLA | 29 sections |
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-018 | INJECTION, SOLUTION | 241.70 mg | INTRAVENOUS | BLA | 29 sections |
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-019 | INJECTION, SOLUTION | 483.30 mg | INTRAVENOUS | BLA | 29 sections |
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-019 | INJECTION, SOLUTION | 483.30 mg | INTRAVENOUS | BLA | 29 sections |
Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-019 | INJECTION, SOLUTION | 483.30 mg | INTRAVENOUS | BLA | 29 sections |